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During 1992, the International Life
Sciences Institute's Risk Science Institute,
in partnership with the U.S. Environmental
Protection Agency (EPA), Office of
Pesticide Programs (OPP), formed a work-
ing group to examine the relationship(s)
between chemically induced mammary
tumors in laboratory rodents and human
breast cancer. Specifically, the working
group composed of scientists from govern-
ment, industry, and academia was asked to
consider five questions: Is a dose-related
increase in mammary tumor incidence in
rodents a credible indicator for potential
human risk? Is the mechanism of tumor
development partially or completely medi-
ated by hormones? Does the mechanism of
carcinogenic response function with or
without a threshold? How do various routes
of exposure (e.g., oral, inhalation, subcuta-
neous) affect rodent mammary carcinogene-
sis and how should such information be
used to select an appropriate animal model
for human risk assessment? What informa-
tion and methodology should be used to
estimate potential human risk?
Through subsequent meetings and dis-
cussions, it became clear that a fundamental
barrier to addressing these questions was the
absence of data on the initiation and pro-
gression of chemically induced mammary
tumors in women. It also became apparent
that a thoughtful comparative analysis of
the role that reproductive hormones play in
rodent mammary tumorigenesis and human
breast carcinogenesis would be critical to
addressing such questions. If modes of
action, modulatory activities, and temporal
influences of hormones on tumorigenic
processes could be established, hormonal
effects could potentially be separated from
chemical effects, which would facilitate
broader understanding of mammary
tumorigenesis. Indeed, the late Eu
Paynter of the OPP initiated just su
review during the late 1980s. U
Paynter's work as a starting point,
Russo accepted the working group's ir
tion to undertake this critical review c
state of the science and to discuss
factors that might be relevant to reso
these issues.
Mammary Gland Neoplasia
The accompanying report, "Mami
Gland Neoplasia in Long-term Ro
Studies," by Russo and Russo (1) i
result of this effort. It carefully exan
the developmental biology ofthe man
ry gland in rodents and in humans ii
absence of known exposure to xenol
chemicals, noting that there are dis
anatomical and developmental differi
between the mammary glands of
mice, and humans. These differe
become more apparent when the is
ences ofparity, lactation, gland involu
and other physiologic processes on th
sue are considered.
When the influence of reprodu
and other hormones is examined, the
ferences between the mammary glani
rodents and humans are even more
dent. Rodent studies employing ovari
my and hormonal replacement the
underscore the importance of
endocrine milieu in mammary gland c
opment and involution.
Hormone-dependent neoplasia v
significantly between species and an
strains within a species. The inciden
mammary tumors among untreated fe
rats is variable, 20%-60% after 2 year
In contrast, the overall lifetime incic
of breast cancer among women ir
United States is about 12% (3). Fe
rats and humans develop mammary tumors
y*ie: of unknown etiology that are hormonally
rity regulated to various degrees. Although these
types of mammary tumors in mice also are
tific susceptible to endocrine-mediated regula-
wa1.: tion, most are associated with infection by
mary mouse mammary tumor virus. Rodent
eom- mammary gland tumors seldom metasta-
may size, reflecting another fundamental differ-
dcEl ence between most human breast cancer
.C.O.,.t.,, and rodent mammary tumors.
From an experimental perspective, the
long latency and variable incidence of
mammary tumors among untreated female
gene rats limits the practical utility of studying
ich a such tumors as models of human disease.
Jsing Genotoxic agents such as dimethylbenz(a)-
Irma anthracene (DMBA), N-methyl-N-
ivita- nitrosourea (MNU), and 3-methylcholan-
)f the threne (MCA) are among the most com-
those monly used compounds to elicit mammary
lving gland tumors in rodents. These agents are
thought to act as initiators within the con-
text ofthe multistage model ofcarcinogene-
sis. Tumor promotion in mammary tissue
mary may be hormonally mediated because the
dent expression oftumorigenicity following initi-
s the ation with such genotoxic agents is deter-
nines mined, at least in part, by age-related
nma- endocrine kinetics.
n the In mice, tumors induced by such com-
Hiotic pounds have a long latency and require
,tinct multiple exposures. In contrast, such
ences tumors can be elicited in rats after a single
rats, exposure during a critical period in postna-
nces tal development and have a much reduced
nflu- latency period. The incidence and number
ttion, of chemically induced tumors vary with
e tis- dose and route of exposure and between
different strains of rats administered identi-
Lctive cal doses by identical routes. Although there
e dif- are certain anatomic, histologic, and devel-
ds of opmental similarities between the mamma-
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912Commentary* Mammary gland neoplasia
or no direct evidence that these or other
genotoxic agents do or do not induce
breast cancer in women. However, such
compounds can induce mutations and/or
neoplastic transformation of human breast
epithelial cells in vitro.
Epidemiological studies have generally
failed to identifyspecific chemical exposures
or other factors that contribute substantive-
ly to the likelihood of developing breast
cancer. Because breast cancer risk is associ-
ated with nulliparity, late first full-term
pregnancy, early menarche, late menopause,
and exposure to ionizing radiation at a
young age (4), some have suggested that
breast cancer may be initiated by exposure
to carcinogenic compounds during a nar-
rowwindow ofopportunity extending from
menarche until the time of the first full-
term pregnancy (5). Studies of chemical
exposures of susceptible subpopulations of
women, e.g., those expressing the BRCA1
(6) or BRCA2 (7) gene products, may
provide the opportunity to better under-
stand the relationship between human
breast cancer and chemical exposure.
Underlying all such generalizations is
an extensive and complex literature charac-
terizing the modulatory effects ofreproduc-
tive and other hormones on all aspects of
mammary gland growth, development, and
disease. A plethora of endocrine interac-
tions can permanently affect mammary
gland structure, organization, and function
as well as altering, at least in rodents, the
response to exposure to mammary tumor-
inducing chemicals. Ovarian and placental
hormones, pituitary and thyroid hormones,
androgens, and insulin have all been
demonstrated to affect the tumorigenic
responses of rats exposed to genotoxic
mammary carcinogens. Similarly, various
growth factors, e.g., inhibin, fibroblast
growth factors, and other cytokines, can
modulate the development and growth of
chemically induced mammary tumors in
rats. Although the complex hormonal envi-
ronments associated with the rat estrous
cycle and the human menstrual cycle differ
in detail, the modulatory effects ofrat hor-
mones on mammary tumor development
and growth raise the possibility of similar
hormonal modulation of human breast
cancer. Indeed, studies ofwomen undergo-
ing ovariectomy, estrogen replacement
therapy, and tamoxifen therapy as a treat-
ment for breast cancer provide evidence of
endocrine involvement in human disease.
Relevance for Risk
Assessment
The impetus for the review by Russo and
Russo (1) was to evaluate the relevance of
findings of chemically induced mammary
tumors in rodents for human health risk
assessment. To address this issue, it is
appropriate to consider their findings in
light ofthe questions and issues raised with
the working group.
Is a dose-related increase in mammary
tumor incidence in rodents a credible indi-
catorfor potential human risk? In the
absence of evidence to the contrary, the
EPA considers findings of mammary
tumors in chemical-exposed rodents
indicative of the potential of the chemical
to cause cancer in humans (e.g., breast can-
cer in women). Although the report by
Russo and Russo (1) identifies certain dif-
ferences as well as similarities between the
mammary glands of rodents and humans,
these findings do not substantively chal-
lenge the EPA's current assumption. The
paucity of human data with respect to
chemical exposure precludes determination
of whether such findings are truly predic-
tive of human risk. The issue is further
confounded by the observation that most
ofthe chemicals that elicit mammary gland
tumorigenesis in rodents are genotoxic
agents and represent only a small fraction
of the compounds to which women are
likely to be exposed. From a risk assess-
ment perspective, consideration of factors
including dose response, route ofadminis-
tration, and mode/mechanism of action
will influence assessment of the relevance
ofthe results ofthe animal studies for pre-
dicting the response of women. Relevance
also will be influenced by the type, inci-
dence, number, and size of the chemically
induced tumors and the occurrence of
tumors in other tissues and organs.
Is the mechanism ofmammary tumor
developmentpartially or completely mediat-
ed by hormones?Russo and Russo (1) indi-
cate that mammary tumorigenesis can be
modulated by hormones. Although there is
evidence that ovariectomy and the subse-
quently ablated hormonal microenviron-
ment can inhibit tumor development and
growth, the synergistic, agonistic, and antag-
onistic relationships among the various hor-
mones that are known to influence rodent
mammary tumors suggest that they are
modulatory in effect. There is dearly a need
to better understand the basis for such mod-
ulatory effects and the implications that hor-
monally modulated rodent mammary
tumors havefor breast cancer in women.
Does carcinogenic response operate with
or without a threshold? The report by
Russo and Russo (1) does not address this
issue. This concern reflects the observation
that estrogen and other hormones which
modulate mammary tumorigenesis operate
through receptors. In at least some
ligand/receptor systems, a threshold num-
ber ofreceptors must be occupied to elicit a
full biologic response. Whether or how this
applies in the consideration of chemically
induced mammary tumors remains to be
determined. Although mammary carcino-
gens may act through the estrogen or other
hormone receptors, endocrine disruption
may occur during hormone synthesis,
secretion, or transport, or at the level of-
second messenger activation or function
(8). The uncertainty in our understanding
of the relationships between the estrogen
receptor and its various agonistic and
antagonistic ligands is illustrative of the
complexity of this issue. For example, the
responses ofcells bearing mutated estrogen
receptors may be stimulated by tamoxifen
but inhibited by estradiol (9).
How do various routes ofexposure
affect rodent mammary tumorigenesis and
how should such information be used to
select an appropriate animal modelfor
human risk assessment? Various routes of
administration have been used in the study
of rodent mammary tumorigenesis. In the
case of DMBA, tumors are typically
induced by intragastric administration,
while MNU-induced tumors can be
induced by intravenous or subcutaneous
administration. However, carefully selected
doses of DMBA and MNU administered
by different routes to animals of a single
strain elicit similar incidences of tumors
with similar latency periods. Such observa-
tions suggest that various routes of expo-
sure may be acceptable for hazard charac-
terization studies, but the evidence is limit-
ed with respect to the number and types of
compounds considered. Ideally, the
route(s) of exposure used during rodent
studies to assess the carcinogenic potential
of chemicals should reflect the most likely
or significant route of potential human
exposure. Given the dearth of information
about chemically induced human breast
cancer, it seems premature to select a single
animal model or route for use in hazard
identification studies. Even suggesting
combinations of models and routes would
be more speculative than informed.
What information and methodology
shouldbe usedto estimatepotentialhuman
risk?Clearly there is a need to make better
use of human data by designing better
studies or asking better questions of exist-
ing databases (10). Occupational exposure
studies may help us to identify and under-
stand some aspects of chemically induced
breast cancer. Perhaps more information
can be extracted from rodent carcinogenici-
ty studies that would facilitate interpreta-
tion of the results. Better characterization
of test compound pharmacokinetics and
pharmacodynamics would enhance under-
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standing. Outside ofthe current 2-year car-
cinogenicity bioassay, further animal stud-
ies of the etiologic factors associated with
carcinogenicity in various test species may
lead to improved assessment ofbreast can-
cer risk in women (11). For example, nor-
mal human breast tissue might be trans-
planted into immunologically incompetent
rodents to determine whether exposure to
certain chemicals elicits the tumorigenic
response observed in normal mice exposed
to the same chemicals. Performing biologi-
cally based dose-response studies in
rodents following full-term pregnancy, lac-
tation, and mammary gland involution
might illuminate the apparent protective
effects of pregnancy and lactation in
humans. Testing chemicals in multiple
strains ofrodents, including those with low
and high incidences of spontaneous mam-
mary gland neoplasms, may elicit greater
appreciation for, and understanding of,
variability in the tumorigenic response.
Pharmacokinetic studies performed using
human breast tissue in vitro and with
rodents both in vivo and in vitro may allow
the use of the parallelogram approach to
risk assessment (12). In vitro studies ofthe
molecular biology and biochemistry ofhor-
mone receptors with respect to measurable
physiologic endpoints, e.g., cell prolifera-
tion or cell activation, are valuable in
understanding and validating the use of in
vivo and in vitro estrogen screening assays
(13). Such studies could provide more sat-
isfying answers to the simply stated but
complex questions raised earlier.
Russo and Russo (1) bring together a
wide array ofobservations and information
about mammary gland tumors in rodents
and humans. The resulting synthesis may
help to channel research efforts and
resources along lines that will ultimately
provide insight into the difficult issues that
confront the risk assessment community
relative to the interpretation ofthe findings
ofmammary tumors in rodents.
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